Technology
Health
Medical

Motus GI Holdings

$3.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.05 (-1.25%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell MOTS and other stocks, options, ETFs, and crypto commission-free!

About

Motus GI Holdings, Inc. engages in the development and commercialization of the Pure-Vu System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. It is a medical technology company dedicated to improving endoscopy outcomes and experiences. Read More The company was founded in September, 2016 and is headquartered in Tirat Carmel, Israel.

Employees
39
Headquarters
Tirat Carmel, Haifa
Founded
Market Cap
62.76M
Price-Earnings Ratio
Dividend Yield
Average Volume
68.84K
High Today
$4.10
Low Today
$3.78
Open Price
$3.98
Volume
16.89K
52 Week High
$10.66
52 Week Low
$2.34

Collections

Technology
Health
Medical
Cancer Prevention
2018 IPO
Asia (Non-China)
Asia

News

Associated PressMar 18

Motus GI Expands Intellectual Property Portfolio with Issuance of New U.S. Patent for the Pure-Vu® System

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Mar 18, 2019--Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that the U.S. Patent and Trademark Office (USPTO) has issued patent No. 10,179,202 titled, “ Systems and methods for cleaning body cavities and for endoscopic steering,” which protects the Company’s flagship product, the Pure-Vu ® System. The Pure-Vu...

17
Simply Wall StMar 12

Those Who Purchased Motus GI Holdings (NASDAQ:MOTS) Shares A Year Ago Have A 13% Loss To Show For It

Motus GI Holdings, Inc. (NASDAQ:MOTS) shareholders should be happy to see the share price up 27% in the last quarter. But that doesn’t change the reality of under-performance over the last twelve months. In fact the stock is down 13% in the last year, well below the market return. See our latest analysis for Motus GI Holdings With just US$45,000 worth of revenue in twelve months, we don’t think the market considers Motus GI Holdings to have proven its business plan. You have to wonder why venture capitali...

64
Associated PressFeb 19

Motus GI Announces Publication of Pure-Vu® System Clinical Study Data in Peer-Reviewed Journal of Clinical Gastroenterology

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Feb 19, 2019--Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, announced today that its manuscript titled, “ , ” has been published in the peer-reviewed . The Company’s flagship product, the Pure-Vu® System, is a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colo...

52

Earnings

-$0.33
-$0.31
-$0.28
-$0.26
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.32 per share
Actual
Expected Mar 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.